CRC Research Update — August 24, 2026
Today's colorectal cancer research highlights
side-effects
A collection of 57 issues
Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy
Researchers examined the incidence and risk factors of non-neutropenic enterocolitis—a serious intestinal inflammation—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy. (Clinical Colorectal Cancer)
This
Study identifies risk factors for irinotecan liver toxicity
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Study identifies risk factors for irinotecan liver toxicity
A retrospective study of 229 cancer patients receiving irinotecan chemotherapy identified key risk factors for hepatotoxicity, which could help clinicians monitor and manage this side effect more effectively. (Frontiers in Oncology)
This content
CRC Research Update — August 20, 2026
Today's colorectal cancer research highlights
CRC Research Update — August 18, 2026
Today's colorectal cancer research highlights
Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Toxicity Comparison Tool Helps Patients Choose Between Fruquintinib and Regorafenib
Researchers developed a weighted toxicity score to help patients and clinicians compare side effects between two later-line treatment options, supporting more informed treatment decisions in metastatic colorectal cancer. (Clinical Colorectal Cancer)
CRC Research Update — August 14, 2026
Today's colorectal cancer research highlights
Rare DPYD Variant Linked to Severe Fluoropyrimidine Toxicity
Skip to content
The CRC Digest
▸ TREATMENT
Rare DPYD Variant Linked to Severe Fluoropyrimidine Toxicity
A 50-year-old colorectal cancer patient developed life-threatening grade 3-4 toxicities after adjuvant XELOX; sequencing identified a rare intronic DPYD variant (c.2766+3A>T) that causes exon 21 skipping and profound DPD deficiency, which
CRC Research Update — August 13, 2026
Today's colorectal cancer research highlights
Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Phase III trial launches to prevent oxaliplatin-induced neuropathy in adjuvant treatment
The PROSPER trial will test lecithinized superoxide dismutase (PC-SOD) against placebo to prevent chemotherapy-induced peripheral neuropathy in stage II/III colorectal cancer patients receiving adjuvant mFOLFOX6, following promising phase II